Univariable analysis for PFS and OS in patients receiving R-CHOP/R-CHOP-like regimens
| Risk factors | PFS | OS | ||
|---|---|---|---|---|
| 5-year PFS rate (%) | P value | 5-year OS rate (%) | P value | |
| Age, years (≥ 60 vs. < 60) | 17.1 vs. 46.8 | 0.033 | 48.2 vs. 76.9 | 0.009 |
| Gender (male vs. female) | 35.4 vs. 32.7 | 0.687 | 63.9 vs. 60.0 | 0.450 |
| ECOG PS (0–1 vs. ≥ 2) | 35.2 vs. 29.4 | 0.009 | 65.5 vs. 31.9 | < 0.001 |
| Ann Arbor stage (I–II vs. III–IV) | 56.2 vs. 20.6 | < 0.001 | 82.5 vs. 49.2 | < 0.001 |
| COO subtype (GCB vs. non-GCB) | 30.2 vs. 34.9 | 0.738 | 65.4 vs. 61.2 | 0.533 |
| Primary site (nodal vs. extranodal) | 31.7 vs. 45.0 | 0.771 | 63.0 vs. 62.2 | 0.539 |
| Extranodal involvement (< 2 vs. ≥ 2 sites) | 38.6 vs. 22.8 | 0.013 | 72.7 vs. 38.7 | < 0.001 |
| LDH (elevated vs. normal) | 25.6 vs. 46.0 | 0.001 | 47.6 vs. 80.8 | < 0.001 |
| IPI score (0–2 vs. 3–5) | 45.3 vs. 18.6 | < 0.001 | 76.6 vs. 39.5 | < 0.001 |
| BCL2 IHC (≥ 60% vs. < 60%) | 28.0 vs. 31.1 | 0.143 | 64.5 vs. 60.0 | 0.856 |
| DEL (yes vs. no) | 38.6 vs. 39.5 | 0.361 | 52.1 vs. 66.6 | 0.595 |
| TP53 mutation (yes vs. no) | 29.8 vs. 35.5 | 0.014 | 53.4 vs. 66.3 | 0.047 |
| BCL2 alteration (yes vs. no) | 13.7 vs. 40.8 | 0.003 | 38.5 vs. 70.9 | 0.036 |
| BCL2 mutation (yes vs. no) | 35.1 vs. 31.3 | 0.67 | 67.0 vs. 61.4 | 0.671 |
| BCL2GA/AMP (yes vs. no) | 0 vs. 38.3 | < 0.001 | 22.1 vs. 69.6 | 0.009 |
| BCL2 translocation (yes vs. no) | 0 vs. 36.7 | 0.116 | 68.6 vs. 61.8 | 0.778 |
| MYC alteration (yes vs. no) | 33.5 vs. 34.3 | 0.501 | 42.8 vs. 66.6 | 0.137 |
| MYC mutation (yes vs. no) | 39.7 vs. 33.1 | 0.845 | 65.2 vs. 61.4 | 0.804 |
| MYC translocation (yes vs. no) | 18.5 vs. 35.1 | 0.097 | 21.0 vs. 66.6 | 0.062 |
| NOTCH1 alteration (yes vs. no) | 47.1 vs. 32.4 | 0.813 | 67.2 vs. 60.9 | 0.398 |
| MYD88 mutation (yes vs. no) | 13.7 vs. 39.9 | 0.094 | 53.3 vs. 66.7 | 0.271 |
| MYD88 L265P mutation (yes vs. no) | 34.4 vs. 34.8 | 0.812 | 73.7 vs. 61.2 | 0.807 |
| MYD88 other mutation (yes vs. no) | 13.9 vs. 38.3 | 0.126 | 48.6 vs. 67.0 | 0.339 |
| CD79B mutation (yes vs. no) | 39.2 vs. 32.0 | 0.978 | 53.4 vs. 64.6 | 0.066 |
| BCL6 alteration (yes vs. no) | 41.6 vs. 34.4 | 0.195 | 67.9 vs. 61.6 | 0.397 |
| BCL6 translocation (yes vs. no) | 66.7 vs. 30.6 | 0.094 | 85.6 vs. 60.0 | 0.219 |
| BCL6 mutation (yes vs. no) | 34.2 vs. 52.5 | 0.116 | 87.5 vs. 59.7 | 0.178 |
Bold indicates significance. PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; PS, performance status; COO, cell of origin; IPI, International Prognostic Index; LDH, lactate dehydrogenase; IHC, immunohistochemistry; DEL, double-expressor lymphoma; GA, gain; AMP, amplification.